ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

QLS2416

A development code. Also written as “QLS2416 Injection”.

Its studies are mostly in Lupus Erythematosus, Systemic, led by Qilu Pharmaceutical.

Furthest: phase 1, since Oct 23, 20261 company-led study, 1 open or runningNext primary completion: Jun 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical11 open or runningphase 1since Oct 23, 2026Oct 23, 2026Jun 2029phase 1 · NCT07906145

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 23, 2026First study: phase 1 study in Lupus Erythematosus, SystemicFirst studyNCT07906145 · 76 planned

Ahead

  1. Jun 2029Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT07906145

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07906145Lupus Erythematosus, Systemic1Not yet recruitingJun 202976

How it is read

Names in the registry

  • “QLS2416 Injection”, 1 entry

Codes read as this program: QLS2416.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.